The looming threat of bedaquiline resistance in tuberculosis

Chen-Yuan Chiang, Arnaud Trébucq, Alberto Piubello, Hans L. Rieder, Valérie Schwoebel, Armand Van Deun

Source: Eur Respir J, 55 (6) 2000718; 10.1183/13993003.00718-2020
Journal Issue: June
Disease area: Respiratory infections

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Chen-Yuan Chiang, Arnaud Trébucq, Alberto Piubello, Hans L. Rieder, Valérie Schwoebel, Armand Van Deun. The looming threat of bedaquiline resistance in tuberculosis. Eur Respir J, 55 (6) 2000718; 10.1183/13993003.00718-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The problem of one drug resistance in tuberculosis
Source: Eur Respir J 2006; 28: Suppl. 50, 858s
Year: 2006

Multidrug- and extensively drug-resistant tuberculosis: an emerging threat
Source: Eur Respir Rev 2009; 18: 195-197
Year: 2009


Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?
Source: Eur Respir J, 55 (2) 1901908; 10.1183/13993003.01908-2019
Year: 2020



Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country
Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis
Year: 2008


Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors
Source: Eur Respir J , 49 (3) 1601719; DOI: 10.1183/13993003.01719-2016
Year: 2017


Molecular surveillance of multi-drug resistant tuberculosis in Europe
Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis
Year: 2007


Primary drug resistance against mycobacterium tuberculosis in a high burden country
Source: Eur Respir J 2006; 28: Suppl. 50, 587s
Year: 2006

Multidrug resistance of M. tuberculosis and its infuence on treatment efficiency of new detected patients with pulmonary tuberculosis in penitentiary institutions of Belarus
Source: Eur Respir J 2007; 30: Suppl. 51, 272s
Year: 2007

Mycobacterium tuberculosis drug resistance surveillance in Belarus
Source: Eur Respir J 2005; 26: Suppl. 49, 199s
Year: 2005

The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs
Source: Eur Respir J 2005; 26: Suppl. 49, 654s
Year: 2005

Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Source: Eur Respir J 2016; 48: 582-585
Year: 2016


Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases
Source: Eur Respir J 2008; 31: 1155-1159
Year: 2008



Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance
Source: Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017
Year: 2017



Tuberculosis 1995–2004: evaluation of the resistance of mycobacterium tuberculosis to anti-TBC drugs in Greece
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
Year: 2006

Mefloquine as a potential drug against multidrug-resistant tuberculosis
Source: Eur Respir J 2015; 46: 1503-1505
Year: 2015


Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?
Source: Eur Respir J 2012; 40: 9-11
Year: 2012


Our experience in multi drug resistant tuberculosis (MDR TB) treatment
Source: Eur Respir J 2005; 26: Suppl. 49, 652s
Year: 2005

Strategies against multidrug-resistant tuberculosis
Source: Eur Respir J 2002; 20: 66S-77S
Year: 2002



Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use
Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017
Year: 2017